Showing 5 posts of 80 posts found.

Daiichi Sankyo gains rights to potential blockbuster cancer drug

March 2, 2011
Research and Development BRAF protein, Daiichi Sankyo, PLX4032, Plexxikon, melanoma, personalised medicine

Daiichi Sankyo has purchased US-based discovery firm Plexxikon for $805 million, gaining access to its potential blockbuster melanoma drug PLX4032. …

Advanced melanoma

Melanoma: intense competition to be the next milestone treatment

February 9, 2011
Research and Development BRAF V600 mutation, Cancer, Tasigna, cancer research, melanoma, tremelimumab

A flurry of new data has emerged in the recent months from an industry-wide pipeline of cancer drugs which could …

GlaxoSmitKline's headquarters

GSK skin cancer drugs moves into phase III

January 25, 2011
Research and Development BRAF V600 mutation, Cancer, Duchenne Muscular Dystrophy, GSK, GSK1120212, GSK2118436, GSK968, GlaxoSmithKline, melanoma, skin cancer

GlaxoSmithKline has begun late-stage trials of two new drugs for advanced or metastatic melanoma patients. GSK2118436 and GSK1120212 are being …

Patient deaths halt Lilly cancer trial

December 15, 2010
Research and Development Eli Lilly, lilly, melanoma, skin cancer, tasisulam

Lilly has been forced to halt phase III trials of its melanoma candidate tasisulam due to serious safety concerns over …


Pfizer signs ‘personalised’ cancer collaboration

January 15, 2010
Research and Development Cancer, Debiopharm, Pfizer, melanoma, skin cancer, tremelimumab

Pfizer is to co-develop its monoclonal antibody treatment for advanced melanoma with Swiss company Debiopharm. The companies will conduct phase …

Latest content